Benzinga | Oct 18, 2021 08:04AM EDT

Vaccitech Announces Data Presentations at AASLD's Liver Meeting 2021

Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced two poster presentations at AASLD's Liver Meeting(r) 2021 showcasing clinical data for VTP-300, the Company's immunotherapeutic in development for the treatment of chronic hepatitis B virus (HBV) infection. The Liver Meeting will be held virtually on November 12-15, 2021.

Poster Title Interim results of HBV001, a Phase 1 study evaluating the safety and tolerability of therapeutic vaccination with ChAdOx1-HBV in healthy volunteers and patients with chronic hepatitis B infection

Publication Number 833

Session Title Hepatitis B: Therapeutics: New Agents

Presenter Tamsin Cargill, Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, UK

Poster Title Phase 1b/2a study of heterologous ChAdOx1/MVA therapeutic vaccination combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB under nucleos(t)ide analogues

Publication Number 835

Session Title Hepatitis B: Therapeutics: New Agents

Presenter Thomas Evans, M.D., Chief Scientific Officer, Vaccitech plc